Neoadjuvant gemcitabine and carboplatin followed by immediate cystectomy may be associated with a survival benefit in patients with clinical T2 bladder cancer
Neoadjuvant cisplatin-based chemotherapy for muscle-invasive bladder cancer (MIBC) is more beneficial for clinical T3/4 than clinical T2 (cT2) disease. The aim of this study was to assess whether neoadjuvant GCarbo has a survival impact on cT2 bladder cancer. We retrospectively reviewed the medical...
Main Authors: | Koie, Takuya, Ohyama, Chikara, Yamamoto, Hayato, Imai, Atsushi, Hatakeyama, Shingo, Yoneyama, Takahiro, Hashimoto, Yasuhiro, Yoneyama, Tohru, Tobisawa, Yuki |
---|---|
Format: | Online |
Language: | English |
Published: |
Springer US
2014
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006118/ |
Similar Items
-
Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan
by: Koie, Takuya, et al.
Published: (2015) -
Both radical prostatectomy following treatment with neoadjuvant LHRH agonist and estramustine and radiotherapy following treatment with neoadjuvant hormonal therapy achieved favorable oncological outcome in high-risk prostate cancer: a propensity-score matching analysis
by: Koie, Takuya, et al.
Published: (2014) -
Renal Function Outcomes and Risk Factors for Risk Factors for Stage 3B Chronic Kidney Disease after Urinary Diversion in Patients with Muscle Invasive Bladder Cancer
by: Hatakeyama, Shingo, et al.
Published: (2016) -
Correction: Renal Function Outcomes and Risk Factors for Risk Factors for Stage 3B Chronic Kidney Disease after Urinary Diversion in Patients with Muscle Invasive Bladder Cancer
by: Hatakeyama, Shingo, et al.
Published: (2016) -
Presence of transient hydronephrosis immediately after surgery has a limited influence on renal function 1 year after ileal neobladder construction
by: Takuma Narita, et al.
Published: (2017-08-01)